DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Clinical trial NCT06805305 · RECRUITING

Trial details

NCT number: NCT06805305
Sponsor: Diakonos Oncology Corporation
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma (GBM)

Start date: 2025-03-17
Primary completion: 2030-03-01
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.